Lexapro adds long-term data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lexapro labeling replaces long-term efficacy data on racemic parent, citalopram (Celexa), with 36-week data on escitalopram via an Aug. 29 supplemental approval. Lexapro treatment resulted in a significantly longer time to depression relapse vs. placebo in the 274-patient tria